FDA recommends no changes to Lilly's schizophrenia injection use

March 23, 2015 6:34 PM

12 0

(Reuters) - The U.S. Food and Drug Administration said it would not recommend changes to the prescribing or use of Eli Lilly and Co's schizophrenia drug after a review of two deaths.

Elevated levels of the drug, Zyprexa Relprevv, were found in the two patients who died in 2013, three to four days after receiving the injection.

Also read: FDA OKs 2nd gene therapy for blood cancer; 1st for adults

Read more

To category page